Home » Effort Under Way in U.S. to Discourage Pay-for-Delay
Effort Under Way in U.S. to Discourage Pay-for-Delay
December 9, 2011
First-filer generic drugmakers that win patent challenges in U.S. district court, or are not sued by the brand company after filing an abbreviated new drug application, could be forced to share their 180-day market exclusivity under a new bill.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor